Luminex Corporation (NASDAQ:LMNX) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, LMNX is expected to report 3Q20 income of $ 0.20 per share from revenue of $ 105.02 million.
For the full year, analysts anticipate top line of $ 420.61 million, while looking forward to income of $ 0.80 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 106.00 million ~ $ 106.00 million
Full Year 2020 topline are forecasted in a range of$ 352.00 million ~ $ 362.00 million
Click Here For More Historical Outlooks Of Luminex Corporation
Previous Quarter Performance
Luminex Corporation outlined income for the second quarter of $ 0.27 per share, from the revenue of $ 109.52 million. The quarterly revenues developed 31.86 percent compared with the same quarter last year. The consensus estimates are income of $ 0.08 per share from $ 107.33 million in revenue. The bottom line results beat street analysts by $ 0.19 or 237.50 percent, at the same time, top line results outshined analysts by $ 2.19 million or 2.04 percent.
Stock Performance
Shares of Luminex Corporation traded up $ 0.16 or 0.70 percent on Wednesday, reaching $ 23.12 with volume of 382.20 thousand shares. Luminex Corporation has traded high as $ 23.60 and has cracked $ 22.79 on the downward trend
The closing price of $ 23.12, representing a 31.43 % increase from the 52 week low of $ 17.47 and a 44.93 % decrease over the 52 week high of $ 41.69.
The company has a market capital of $ 1.07 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Luminex Corporation will be hosting a conference call at 5:00 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.luminexcorp.com
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism.
